Evolving Pharmacology Of Depression: Beyond The Monoamine Hypothesis
According to the World Health Organization, major depressive disorder (MDD) currently impacts 300 million individuals worldwide and is the leading cause of disability globally. Current treatment strategies for depression are effective in one-third to half of those seeking treatment, leaving a large unmet need for new therapeutic options. Since the 1960’s, traditional pharmacological treatment strategies have centered on modulating serotonin, dopamine, and/or norepinephrine neurotransmitter systems. However, within the last few decades, research has begun to explore other neurotransmitter systems like …
Join PsychU today at no cost for access to this and other premium content!